Long QT Syndrome medical and device therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 5: Line 5:


==Overview==
==Overview==
There are two tratment options in individuals with LQTS: arrhythmia prevention, and arrhythmia termination.
Beta-blockers are first line treatment in LQTs along with electrolyte repletion, and avoidance of triggers (drugs, supplements, loud noises). LQTs is one of the few diseases where genetic testing actually can provide important guidance such as who to put a [[AICD]] (defibrillator) in for primary prevention. <ref>Compton SJ, Lux RL, Ramsey MR, Strelich KR, Sanguinetti MC, Green LS, Keating MT, Mason JW. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation. 1996 Sep 1;94(5):1018-22. PMID 8790040</ref>


==Withdrawal of Drugs and Supplements==
==Primary Prevention==
===Withdrawal of Drugs and Supplements===
Certain medications should be avoided in persons with long QT syndrome, to avoid worsening the condition. These medications include certain [[appetite suppressants]], [[decongestants]], and [[antibiotics]] such as [[erythromycin]]. Illicit drugs such as [[cocaine]] and [[amphetamines]] can be even more dangerous in persons with long QT syndrome.
Certain medications should be avoided in persons with long QT syndrome, to avoid worsening the condition. These medications include certain [[appetite suppressants]], [[decongestants]], and [[antibiotics]] such as [[erythromycin]]. Illicit drugs such as [[cocaine]] and [[amphetamines]] can be even more dangerous in persons with long QT syndrome.


==Correct Electrolyte Disturbances==
===Correct Electrolyte Disturbances===
Illness that cause [[hypokalemia]] due to [[vomiting]] and [[diarrhea]] can aggravate long QT syndrome. Medications that can lower the levels of [[potassium]] in the blood should also be avoided.
Illness that cause [[hypokalemia]] due to [[vomiting]] and [[diarrhea]] can aggravate long QT syndrome. Medications that can lower the levels of [[potassium]] in the blood should also be avoided.


==Primary Prevention==
===Postassium Administration===
The use of potassium supplementation is experimental and is not evidence based.  The hypothesis is that ff the potassium content in the blood rises, the [[action potential]] shortens and it is for this reason that increasing potassium concentration may minimize the occurrence of arrhythmias. It should work best in [[LQT2]] since the HERG channel is especially sensible to potassium concentration, but potassium supplementation is experimental and not evidence based.
 
===Beta Blockers===
===Beta Blockers===
Beta blockers are first line therapy in the treatment of Long QT syndrome.
Beta blockers are first line therapy in the treatment of Long QT syndrome.


Arrhythmia suppression involves the use of medications or surgical procedures that attack the underlying cause of the arrhythmias associated with LQTS.  Since the cause of arrhythmias in LQTS is after depolarizations, and these after depolarizations are increased in states of adrenergic stimulation, steps can be taken to blunt adrenergic stimulation in these individuals.  [[Beta blocker|beta receptor blocking agents]] decrease the risk of stress or catecholamine induced arrhythmias.
Arrhythmia suppression involves the use of medications or surgical procedures that attack the underlying cause of the arrhythmias associated with LQTS.  Since the cause of arrhythmias in LQTS is after depolarizations, and these after depolarizations are increased in states of adrenergic stimulation, steps can be taken to blunt adrenergic stimulation in these individuals.  [[Beta blocker|beta receptor blocking agents]] decrease the risk of stress or catecholamine induced arrhythmias.
===Mexiletine===
[[Mexiletine]] is a [[sodium channel]] blocker. In [[LQT3]] the problem is that the sodium channel does not close properly. Mexiletine closes these channels and is believed to be potentially of use when other therapies fail. It should be especially effective in LQT3 but there is limited evidence to support this recommendation.


===AICD Implantation===
===AICD Implantation===
Genotype and QT interval duration are independent predictors of recurrence of life-threatening events during beta-blockers therapy. Specifically the presence of QTc >500ms and [[LQT2]] and [[LQT3]] genotype are associated with the highest incidence of recurrence. In these patients primary prevention with ICD (Implantable Cardioverster Defibrilator) implantaion can be considered.<ref>Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, Moncalvo C, Tulipani C, Veia A, Bottelli G, Nastoli J. Association of long QT syndrome loci and cardiac events among patients treated
with beta-blockers. JAMA. 2004 Sep 15;292(11):1341-4.[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15367556&query_hl=26&itool=pubmed_docsumPMID: 15367556]</ref>
An [[AICD]] should be implanted if:
An [[AICD]] should be implanted if:
*The QTc is > 550 ms and if it is not [[LQT1]]
*The QTc is > 550 ms and if it is not [[LQT1]]
Line 25: Line 34:
*In infants with 2:1 [[AV block]] (controversial)
*In infants with 2:1 [[AV block]] (controversial)
*In [[JLNS]] (LQTS with deafness) given its malignant propensity (controversial)
*In [[JLNS]] (LQTS with deafness) given its malignant propensity (controversial)
===Sympathetic Denervation===
===Sympathetic Denervation===
Videoscopic Left Cardiac Sympathetic Denervation Surgery is not a cure, but reduces the risk of [[sudden cardiac death]] and is indicated if:
Videoscopic Left Cardiac Sympathetic Denervation Surgery (left [[Stellate ganglion|stellectomy]]) is not a cure, but reduces the risk of [[sudden cardiac death]] and is indicated if:
*The patient does not tolerate [[beta blockers]] or breaks through [[beta blockers]]
*The patient does not tolerate [[beta blockers]] or breaks through [[beta blockers]]
*The patient [[faints]] while on [[beta blockers]]
*The patient [[faints]] while on [[beta blockers]]
Line 34: Line 44:
==Secondary Prevention==
==Secondary Prevention==
Patients with [[Long QT syndrome]] should undergo secondary prevention with [[AICD]] implantation if they sustain an aborted [[cardiac arrest]] or[[sudden cardiac death]].
Patients with [[Long QT syndrome]] should undergo secondary prevention with [[AICD]] implantation if they sustain an aborted [[cardiac arrest]] or[[sudden cardiac death]].
==Arrhythmia prevention==
In 2004 it has been shown that genotype and QT interval duration are independent predictors of recurrence of life-threatening events during beta-blockers therapy. Specifically the presence of QTc >500ms and LQT2 and LQT3 genotype are associated with the highest incidence of recurrence. In these patients primary prevention with ICD (Implantable Cardioverster Defibrilator) implantaion can be considered.<ref>Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, Moncalvo C, Tulipani C, Veia A, Bottelli G, Nastoli J. Association of long QT syndrome loci and cardiac events among patients treated
with beta-blockers. JAMA. 2004 Sep 15;292(11):1341-4.[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15367556&query_hl=26&itool=pubmed_docsumPMID: 15367556]</ref>
* Potassium supplementation. If the potassium content in the blood rises, the action potential shortens and due to this reason it is believed that increasing potassium concentration could minimize the occurrence of arrhythmias. It should work best in LQT2 since the HERG channel is especially sensible to potassium concentration, but the use is experimental and not evidence based.
* [[Mexiletine]]. A sodium channel blocker. In LQT3 the problem is that the sodium channel does not close properly. Mexiletine closes these channels and is believed to be usable when other therapies fail. It should be especially effective in LQT3 but there is no evidence based documentation.
* Amputation of the [[cervical sympathetic chain]] (left [[Stellate ganglion|stellectomy]]). This may be used as an add-on therapy to beta blockers but modern therapy mostly favors ICD implantation if beta blocker therapy fails.
===Arrhythmia termination===
Arrhythmia termination involves stopping a life-threatening arrhythmia once it has already occurred.  The only effective form of arrhythmia termination in individuals with LQTS is placement of an [[implantable cardioverter-defibrillator]] (ICD). ICD are commonly used in patients with syncopes despite beta blocker therapy, and in patients who have experienced a cardiac arrest.
With better knowledge of the genetics underlying the long QT syndrome, more precise treatments will be readily available.<ref>Compton SJ, Lux RL, Ramsey MR, Strelich KR, Sanguinetti MC, Green LS, Keating MT, Mason JW. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation. 1996 Sep 1;94(5):1018-22. PMID 8790040</ref>


==References==
==References==

Revision as of 03:40, 2 October 2012

Long QT Syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Long QT Syndrome from other Diseases

Epidemiology and Demographics

Risk Stratification

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Genetic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Long QT Syndrome medical and device therapy On the Web

Most recent articles

Most cited articles

Review articles

Programs

slides

[1]

American Roentgen Ray Society Images of Long QT Syndrome medical and device therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

on Long QT Syndrome medical and device therapy

CDC onLong QT Syndrome medical and device therapy

QT Syndrome medical and device therapy in the news

on Long QT Syndrome medical and device therapy

Directions to Hospitals Treating Long QT Syndrome

Risk calculators and risk factors for Long QT Syndrome medical and device therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Beta-blockers are first line treatment in LQTs along with electrolyte repletion, and avoidance of triggers (drugs, supplements, loud noises). LQTs is one of the few diseases where genetic testing actually can provide important guidance such as who to put a AICD (defibrillator) in for primary prevention. [1]

Primary Prevention

Withdrawal of Drugs and Supplements

Certain medications should be avoided in persons with long QT syndrome, to avoid worsening the condition. These medications include certain appetite suppressants, decongestants, and antibiotics such as erythromycin. Illicit drugs such as cocaine and amphetamines can be even more dangerous in persons with long QT syndrome.

Correct Electrolyte Disturbances

Illness that cause hypokalemia due to vomiting and diarrhea can aggravate long QT syndrome. Medications that can lower the levels of potassium in the blood should also be avoided.

Postassium Administration

The use of potassium supplementation is experimental and is not evidence based. The hypothesis is that ff the potassium content in the blood rises, the action potential shortens and it is for this reason that increasing potassium concentration may minimize the occurrence of arrhythmias. It should work best in LQT2 since the HERG channel is especially sensible to potassium concentration, but potassium supplementation is experimental and not evidence based.

Beta Blockers

Beta blockers are first line therapy in the treatment of Long QT syndrome.

Arrhythmia suppression involves the use of medications or surgical procedures that attack the underlying cause of the arrhythmias associated with LQTS. Since the cause of arrhythmias in LQTS is after depolarizations, and these after depolarizations are increased in states of adrenergic stimulation, steps can be taken to blunt adrenergic stimulation in these individuals. beta receptor blocking agents decrease the risk of stress or catecholamine induced arrhythmias.

Mexiletine

Mexiletine is a sodium channel blocker. In LQT3 the problem is that the sodium channel does not close properly. Mexiletine closes these channels and is believed to be potentially of use when other therapies fail. It should be especially effective in LQT3 but there is limited evidence to support this recommendation.

AICD Implantation

Genotype and QT interval duration are independent predictors of recurrence of life-threatening events during beta-blockers therapy. Specifically the presence of QTc >500ms and LQT2 and LQT3 genotype are associated with the highest incidence of recurrence. In these patients primary prevention with ICD (Implantable Cardioverster Defibrilator) implantaion can be considered.[2]

An AICD should be implanted if:

  • The QTc is > 550 ms and if it is not LQT1
  • LQT2 in women and the QTc is > 500 ms, with or without symptoms
  • In infants with 2:1 AV block (controversial)
  • In JLNS (LQTS with deafness) given its malignant propensity (controversial)

Sympathetic Denervation

Videoscopic Left Cardiac Sympathetic Denervation Surgery (left stellectomy) is not a cure, but reduces the risk of sudden cardiac death and is indicated if:

Secondary Prevention

Patients with Long QT syndrome should undergo secondary prevention with AICD implantation if they sustain an aborted cardiac arrest orsudden cardiac death.

References

  1. Compton SJ, Lux RL, Ramsey MR, Strelich KR, Sanguinetti MC, Green LS, Keating MT, Mason JW. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation. 1996 Sep 1;94(5):1018-22. PMID 8790040
  2. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, Moncalvo C, Tulipani C, Veia A, Bottelli G, Nastoli J. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004 Sep 15;292(11):1341-4.15367556

Template:WH

Template:WS